Although biomarker data were not consistently reported in these studies, where reported there was evidence that interval BCs had a higher frequency of triple-negative or HER2-positive cancers and a lower frequency of hormone receptor-positive cancers than screen-detected BC (Table 3). The gene discussed is ERBB2; the disease is breast cancer.